REGN
-
EYLEA HD® Shows Positive Phase 3 Results for Macular Edema
Regeneron Pharmaceuticals (REGN) has announced positive results from its Phase 3 QUASAR trial evaluating EYLEA HD® for the treatment of macular edema following retinal vein occlusion (RVO).